Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™
September 19, 2023 08:00 ET
|
Dyadic International, Inc.
Dyadic to receive upfront payment of $0.6 million for product development and licensing its Dapibus™ platform, in addition to potential success fees, milestones, and royalties. JUPITER, Fla., Sept. ...
[Latest] Global Recombinant Human Insulin Market Size/Share Worth USD 55.99 Billion by 2032 at a 8.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
August 25, 2023 16:30 ET
|
Custom Market Insights
Austin, TX, USA, Aug. 26, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Recombinant Human Insulin Market Size, Trends and Insights By Product (Regular...
Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
August 07, 2023 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Human Serum Albumin (HSA) Market to Garner $7,124.9 Million by 2031 with 6.8% CAGR | Research Dive
June 19, 2023 09:05 ET
|
Research Dive
New York, USA, June 19, 2023 (GLOBE NEWSWIRE) -- According to Research Dive’s newly published report, the global human serum albumin (HSA) market is predicted to grow at a stable CAGR of 6.8%,...
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
January 24, 2023 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Business Expansion: Global Albumin Market Estimated to Generate a Revenue of $8,129.1 Million and Grow at 10.1% CAGR in the 2021-2028 Timeframe [175-Pages] | Confirmed By Research Dive
April 27, 2022 09:15 ET
|
Research Dive
New York, USA, April 27, 2022 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global albumin market is estimated to garner a revenue of $8,129.1 million by 2028 and grow...
Vaccines Market revenue to cross USD 83.5 Bn by 2027: Global Market Insights Inc.
June 03, 2021 02:00 ET
|
Global Market Insights, Inc
Selbyville, Delaware, June 03, 2021 (GLOBE NEWSWIRE) -- According to latest report “Vaccines Market by Age Group (Pediatric, Adult), Disease (Cancer, Hepatitis, Pneumococcal Disease, DTP, Dengue,...
AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4)
August 31, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
Vaccines Market value to hit $72.5 billion by 2025: Global Market Insights, Inc.
August 15, 2019 02:30 ET
|
Global Market Insights, Inc
Selbyville, Delaware, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Global Market Insights, Inc., announces a research report on ‘Vaccines Market Trends and Forecast 2019-2025’. The report covers an extensive...
Global Vaccines Market to surpass $65 Bn by 2024: Global Market Insights, Inc.
November 20, 2017 05:00 ET
|
Global Market Insights, Inc
Sellbyville, Delaware, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Global Vaccines Market is poised to cross USD 65 billion by 2024; according to a new research report by Global Market Insights, Inc....